cyrilzakka/clinical-trials huggingface dataset:
Vanderbilt Childhood Obesity Registry

In order to better understand early onset obesity and to identify patients in interested in future research studies, including clinical trials, we aim to develop a registry for patients with early onset obesity.

Obesity is an epidemic effecting the pediatric population. Currently, 17% of children are classified as obese and 32% as overweight. Many of these children develop complications including type 2 diabetes, dyslipidemia, hypertension and hepatic steatosis. Obesity is a global epidemic that lacks effective treatment options. Obesity has many underlying causes including genetic predisposition and environmental factors. Understanding the genetic basis of obesity may allow for more precisely targeted interventions including specific dietary plans and pharmacologic treatments. The most common cause of genetic obesity is haploinsufficiency of the melanocortin-4 receptor (MC4R). In obese adult cohorts, the prevalence of pathogenic MC4R mutations is 1-2%. Commercial testing is available for many obesity syndromes, but the cost is high and charges are not always covered by insurance. Clinicians have little motivation to test patients for MC4R mutations as no treatments are available and it is not clear if genetic testing results change patient behavior. This particular lab and other groups are working to develop novel pharmacologic treatments for obesity syndromes, such as MC4R deficiency. In order to better understand early onset obesity and to identify patients in interested in future research studies, including clinical trials, the investigators aim to develop a registry for patients with early onset obesity.

Eligibility Criteria:
Inclusion Criteria:

1. BMI \>97th percentile for age and gender before 6 years old
2. Able to give written, informed consent/assent

Exclusion Criteria:

1. Diagnosis of Prader-Willi syndrome
2. Use of exogenous steroids or other medications known to cause abnormal weight gain
3. Cushing's syndrome, untreated growth hormone deficiency or untreated hypothyroidism as an etiology for the obesity
4. Hypothalamic obesity (obesity due to a brain tumor, head trauma or other brain lesion)
5. Currently pregnant
A Cohort Study in Newly Diagnosed MZL

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Marginal zone lymphoma (MZL) originates from the marginal zone of lymphatic follicles and can occur in the spleen, lymph nodes and mucosal lymphoid tissues, and the incidence increases with age. The clinicopathological features of each subtype of MZL are heterogeneous, and their clinical manifestations, biology, etiology, and treatment are all quite heterogeneous, and there is still significant uncertainty about the optimal treatment pathway. This prospective, multicenter, cohort study aims to describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of MZL, and to observe the therapeutic efficacy and safety of different treatment modalities.

Eligibility Criteria:
Inclusion Criteria:

* Age≥ 18 years old; Male or female.
* Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors).
* Willing to provide biological samples required for the study, including blood samples and tumor tissue.
* Voluntarily join this study and sign the informed consent form.
* Willing to accept long-term follow-up.

Exclusion Criteria:

* Patients with HIV infection.
* Those who cannot come to the hospital regularly for follow-up.
* Those with comorbidities and speech impairment.
The Effect of Emotional Freedom Technique on Breastfeeding

This study was planned to determine the effect of the emotional liberation technique on breastfeeding in women experiencing motherhood sadness.

Maternity blues is defined as a group of psychological and psychosomatic symptoms that generally affect women within 10-15 days after birth and are not considered a pathological condition. Emotional Freedom Techniques (EFT) is an evidence-based method that combines acupressure with elements from cognitive and exposure therapies. EFT has become widely used in medical and psychological treatment settings in recent years. It is also used as a self-help technique by millions of people every year.

For mothers experiencing motherhood blues, the opportunity to freely express and share their feelings can provide emotional relief. This can help reduce stress and make the mother feel more comfortable. Emotional comfort and support of the mother can positively affect breastfeeding performance. Reducing emotional stress can increase milk production and help the mother have a better breastfeeding experience.

For this reason, this study was planned to determine the effect of the emotional liberation technique on breastfeeding in women experiencing motherhood sadness.

Eligibility Criteria:
Inclusion Criteria:

* Voluntarily agrees to participate in the study,
* Experiencing motherhood blues
* Being over 18 years old

Exclusion Criteria:

* • Leaving the study at any time,

  * Having any obstacle to communication
Partners in Health: A Couples-based Approach to Obesity Prevention

The purpose of this pilot study is to test the feasibility of an innovative, couples based approach to weight management during pregnancy. The primary hypothesis is that a couples-based behavioral weight management program will reduce the rate of gestational weight gain compared to standard care.


Eligibility Criteria:
Inclusion Criteria:

Pregnant Women

* \>18 years old
* 15-22 weeks gestation
* BMI \>= 25
* cohabitating with partner for at least 3 months or recently married
* willing to consent

Non-pregnant Partner

* BMI \>= 25
* cohabitating with partner for at least 3 months or recently married
* willing to consent

Exclusion Criteria:

* Untreated medical or psychological problem
* Inability to be physically active
Impact of Frailty and ICU-AW on Post-ICU Fatigue Self-reported

After a prolonged stay in Intensive Care Unit (ICU), fatigue is the most common symptom reported by patients in the Post Intensive Care Syndrome (PICS). Other complications have been described, including ICU-acquired weakness, leading to increased morbidity and mortality after discharge. Actually, risk factors associated with post-ICU fatigue self-reported are not really known.

Frailty, defined as a decrease in physiological reserves leading to an alteration in the mechanisms of adaptation to stress, increases the incidence of PICS and could therefore be a cause of post-ICU fatigue self-reported.

The aim of this study is to identify a relationship between markers of frailty, ICU-AW, ICU story and the post-ICU fatigue self-reported 6 months discharge in patients with prolonged ICU stays.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a length of stay in intensive care \> or equal to 7 days, or mechanical ventilation \> or equal to 5 days

Exclusion Criteria:

* Scheduled surgery with admission in ICU
* Pregnancy
* Guardianship
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

This study is divided into two parts. One is the patients with neoadjuvant therapy. After 3 cycles of neoadjuvant therapy, to observe whether the patients with Clostridium butyricum live tablets have better neoadjuvant therapy efficacy. The other was in patients with adjuvant therapy to see if adjuvant therapy combined with Clostridium butyricum could prolong the patient's prognosis.

Eligibility Criteria:
Inclusion Criteria:

For Neoadjuvant therapy:

* T2-T4aN0M0 bladder patients

For Adjuvant therapy:

* Postoperative pathological stage T3-T4 and/or lymph node metastasis were positive.

Exclusion Criteria:

* The researchers evaluated the patients who could not tolerate radical surgery;
* Previously received systemic chemotherapy or immunotherapy;
* There are active autoimmune diseases requiring systemic treatment or other diseases requiring long-term use of a large number of hormones and other immunosuppressants;
* Have had major surgery or major trauma within 28 days before joining the group;
* Vaccinated with live vaccine within 28 days before joining the group.
diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)

This study aims to randomly assign individuals with type 2 diabetes into the ENHANCED randomized control trial. The study is being conducted by the Minneapolis Heart Institute Foundation (MHIF) and will have two study sites 1) Hutchinson Health and 2) New Ulm Medical Center. The study is primarily funded through the Academy of Nutrition and Dietetics (AND).

The study will examine the impact of a registered dietitian-led, primary care integrated, telemedicine program on diabetes care measures (the 'D5') over one year as compared to usual care. The D5 goals include: blood pressure \<140/90 mmHg, taking a statin as appropriate, A1c \<8%, not using tobacco and taking an aspirin as appropriate.

Individuals will be invited to attend a baseline visit where they will have lab work done, anthropometrics (height, weight, waist circumference) and complete a lifestyle assessment. They will formally consent to participation by signing a study consent form. The same measures will be collected after completion of the one year study.

Study participants will receive two sessions of free lab work, a diabetes education book, and brief coaching with a registered dietitian/certified diabetes educator. In addition, those randomized to the phone coaching will have access to a registered dietitian/certified diabetes educator on a monthly basis for one year of personalized health coaching for free. The intent of this coaching is to help individuals achieve diabetes "optimal" care or meeting all 5 Diabetes Care measures (blood glucose, blood pressure, tobacco use, statin and aspirin use).

This program is designed to complement usual clinic-based primary care, with coaches documenting lab, biometrics and medication adjustments in the EHR, along with documenting phone encounters and communicating directly with patients' PCPs as needed. Documentation in the EHR uses an order created specifically for the study indicating the patient's research status.

Lab work required as part of this research study at baseline and 12 months is covered by the study. Any lab work and/or medication co-pays or fees outside of the baseline and 12 month study visits are the responsibility of the patient and/or their insurance

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of Type 2 Diabetes
2. Individuals who are not meeting 3 or more D5 goals,
3. Have had a visit with a provider within the last 2 years

Exclusion Criteria:

1. Type 1 Diabetes
2. Chronic kidney disease (GFR \<30)
3. HIV
4. Institutional residence
5. Major cognitive or language barrier (as determined by program enrollment staff)
6. Other active end-stage disease (e.g., late stage cancer or pulmonary disease)
7. Actively receiving cancer treatment
8. Pregnant
A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours

OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and pharmacogenetic biomarker study is initiated and funded by the investigators, and will be conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and pharmacogenetic samples will be collected, stored and analysed at the local laboratory of the study site (Cancer Science Institute, National University Health System, Singapore, Dr Boon-Cher Goh).


Eligibility Criteria:
Inclusion Criteria:

Advanced Solid Tumor

Exclusion Criteria:

Non advanced solid tumor
Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients

This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients. The primary outcome measure was the proportion of patients with severe/critical illness within 28 days.


Eligibility Criteria:
Inclusion Criteria:

1. Living in a nursing home who has taken or intends to take azvudine tablets depending on their condition;
2. Mild/normal subjects who are SARS-CoV-2 RT-RCR positive or antigen-positive;
3. Subjects have at least one or more of the following clinical symptoms of COVID-19 in the 24 hours prior to initial administration, including but not limited to: fever, cough, sore throat, stuffy or runny nose, headache, muscle pain, nausea, vomiting, diarrhea, shortness of breath or difficulty breathing, chills or chills;
4. Volunteer to participate in the experiment and sign the informed consent in person or complete the informed consent over the phone.

Exclusion Criteria:

1. Subjects have received antiviral therapy, such as Paxlovid and SARS-CoV-2 monoclonal antibody therapy (except previous treatment for COVID-19 infection) before entering the study;
2. Shortness of breath, RR≥30 times/min or resting state, oxygen saturation of finger when sucking air ≤93%;
3. Mechanical ventilation is required or expected to be urgently required;
4. Severe infections requiring systemic treatment within 14 days prior to initial medication;
5. Use of other antiviral drugs (such as anti-HIV, hepatitis B, and hepatitis C drugs) within 14 days prior to the first medication.
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

This study was a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for intravitreal injection in nAMD patients.

The observational period was 1 year (52 weeks) from the first brolucizumab administration in the primary treated eye.

However, if brolucizumab was discontinued in the primary treated eye and if the treatment was discontinued less than 52 weeks observation period, the observation period was to be up to 90 days after the last dose of this drug. This was set in order to collect data as much as possible based on the clinical effect of the drug. If 30 days after the last dose of this drug in a discontinued patient exceeds 52 weeks of the observation period, the patient was to be monitored for adverse events until 30 days after the last dose of this drug.

Eligibility Criteria:
Inclusion Criteria:

1. Patients must provide written consent to cooperate in this study before treatment with Beovu kit for intravitreal injection
2. Patients using Beovu kit for intravitreal injection for the first time for the following indication:

   * Indication: age-related macular degeneration with subfoveal choroidal neovascularization

Exclusion Criteria:

1. Patients with a history of treatment with a drug containing the same ingredient (brolucizumab; investigational drug or post-marketing clinical study drug) as Beovu kit for intravitreal injection
MA-ASAP at Independent Abortion Clinics: A Demonstration Project

In this study, the investigators propose to conduct a parallel study to MA-ASAP (ClinicalTrials.gov Identifier: NCT05278780) at an independent clinic.

In this study, the investigators propose to conduct a parallel study to the MA-ASAP pilot study (ClinicalTrials.gov Identifier: NCT05278780) at one or more independent abortion clinics. This new study will be similar in structure to pilot study, except that all completed screening questionnaires will be sent to the study site rather than only those deemed eligible according a computer algorithm. The investigators expect that this change will better serve the needs of both clinics and patients, and it will also allow us to assess whether the algorithm is overly restrictive, i.e., whether it is excluding patients who are in fact eligible for MA. The primary goal of the study is to collect data on feasibility of the approach and safety. Secondarily, the investigators aim to assess the ability of a defined set of responses to the screening questionnaire to predict the clinician's decision about whether a clinical consultation is needed.

Eligibility Criteria:
Inclusion Criteria:

* Can speak and read English
* Has an address in a state where the study clinicians are licensed to practice medicine and where the service is legal
* Is old enough to consent to abortion and study participation without parental consent in the study state
* Has reviewed the study website
* Has had a positive pregnancy test
* Has signed the study informed consent form (ICF), which will be included within the questionnaire
* Is pregnant with a gestational age of ≤77 days from last menstrual period
* Desires MA
* Has no symptoms of or risk factors for ectopic pregnancy
* Has no medical contraindications to MA, specifically:

Hemorrhagic disorder or concurrent anticoagulant therapy Chronic adrenal failure Concurrent long-term systemic corticosteroid therapy Inherited porphyria Allergy to mifepristone or misoprostol, or other prostaglandin

* Is not asked by the site to have a synchronous consultation with clinician OR facility-based tests such as ultrasound, laboratory tests, examination, etc.
* Is comfortable obtaining the abortion pills without a pre-treatment ultrasound and without speaking by phone or video with the abortion provider.
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients with Type 2 Diabetes Mellitus

A multicenter, randomized, double-blind, placebo-controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2203

A multicenter, randomized, double-blind, placebo-controlled, parallel, phase Ⅲ study

Eligibility Criteria:
Inclusion Criteria:

* Type 2 Diabetes Mellitus

Exclusion Criteria:

* Type 1 Diabetes Mellitus
* The subject not meet the specified HbA1c and FPG
Neurotrophins Implications in Primary Sjögren Syndrome

Neurotrophins (NTs) constitute a family of growth factors, which regulated differentiation, proliferation, and survival of both neuronal cells and astrocytes. In recent years, several studies have provided evidences that the cellular effects of NGF " Nerve Growth Factor ", BDNF " Brain-Derived Neurotrophic Factor " and NT-3 are not limited to the nervous system. Indeed, neurotrophins and their receptors are widely expressed on non neuronal cells. Data concerning the implication of NTs and their receptors in the immune system maturation and in the regulation of normal and pathological immune responses are numerous and suggest the existence of a specific "neuro-immunomodulation" through these neuropeptides.

The aim of the study is to compare Sjögren's syndrome systemic activity to seric, lymphocytic and conjunctival levels of NTs (i.e NGF, BDNF and NT-3). A preliminary study has previously pointed out the link between high BDNF seric levels and Sjögren's systemic activity. The increased levels of BDNF were correlated to T cell activation. A similar correlation between high NGF level and hypergammaglobulinemia was also pointed out.

2 supplementary blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up.

Salivary sicca syndrome will be evaluated with un-stimulated salivary flow rate. Saliva fluid will be collected from NTs levels determination (ELISA). Ocular sicca syndrome will be evaluated by Schirmer tests and Lissaline green test. A conjunctival cytological impression will be done in order to determine NTs conjunctival production by flow cytometry.

Eligibility Criteria:
Inclusion Criteria:

Arm : primary Sjögren syndrome:

* All patients must fulfill the revised criteria for primary Sjögren syndrome.
* Age of entry into the study ≥ 18 yrs.
* Affiliated or profit patient of a social security system.
* Informed consent signed up.

Arm : healthy volunteers:

* All patient free of autoimmune disease.
* Age of entry into the study ≥ 18 yrs.
* Affiliated or profit patient of a social security system.
* Informed consent signed up.

Exclusion Criteria:

* Patient with psychiatric disorders not related with antiphospholipid syndrome and / or cerebral complication of SGSp.
* Addictive behaviors (alcoholism, cocaine or opioid abuse).
* Patient with anti-depressive drugs.
* Patient with concurrent malignancy
* Pregnancy
* Patients under measure of maintenance of justice.
* Patients unable to understand or to participate to the study.
* Child and major patients making the object of a measure of lawful protection.
* Patients deprived of freedom.

Exclusion criteria for control group

* Autoimmune disease.
* Steroid treatment (\>20 mg/day).
* Immunosuppressive treatment.
* Concurrent malignancy.
* Concurrent psychiatric disorders.
* Anti-depressive drugs.
* Pregnancy.
Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception

Intussusception is one of the most frequent causes of acute bowel and second most common cause of acute abdominal pain in pediatric age .95 % of cases are idiopathic, the rest are either due to pathological lead point or post operative. Treatment of intussusception must start with medical resuscitation, then radiological or operative reduction of intussusception.

Our surgery team has used hydrocortisone with the medical resuscitation to improve the success rate of pneumatic reduction and decrease the number of reduction trials.

Experimental group will be given single dose IV Hydrocortisone 10 mg/kg with Resuscitation before attempting first trial of pneumatic reduction and the outcome measured.

Control group will be given Saline 100 ml IV single injection with Resuscitation before attempting first trial of pneumatic reduction and the outcome measured.

Eligibility Criteria:
Inclusion Criteria:

* Infantile Intussusception

Exclusion Criteria:

* Peritonitis Pneumoperitoneum Morbid patients
Comparison Study of CoaguChek XS PT and Laboratory Innovin PT by NTUH Lab Medicine

Comparison Study of CoaguChek XS PT and Laboratory Innovin PT by NTUH Lab Medicine

This trial is going to proceed in two phases: Familiarization Phase and Evaluation Phase. The Preliminary Comparison Study consists of ten (10) patients being tested with the CoaguChek system and the laboratory reference method. This preliminary study is intended to help familiarize the operator with the dosing of the CoaguChek XS PT strips and to serve as an indicator as to whether some of the variables. Evaluation Phase consists of testing seventy (70) patient samples with the CoaguChek XS system and with the laboratory method.

Eligibility Criteria:
Inclusion Criteria:

* Warfarin continuously treated patients

Exclusion Criteria:

* Warfarin recently discontinuous treatment